These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 36142824)

  • 1. Healthy-like CD4
    Schneider J; Kuhlmann L; Xiao Y; Raha S; Bernhardt G; Stadler M; Thol F; Heuser M; Eder M; Ganser A; Ravens S; Förster R; Prinz I; Koenecke C; Schultze-Florey CR
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The association of CD25 expression on donor CD8+ and CD4+ T cells with graft-versus-host disease after donor lymphocyte infusions.
    Mutis T; Aarts-Riemens T; Verdonck LF
    Haematologica; 2005 Oct; 90(10):1389-95. PubMed ID: 16219576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
    Xia G; Truitt RL; Johnson BD
    Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant.
    Alyea EP; Soiffer RJ; Canning C; Neuberg D; Schlossman R; Pickett C; Collins H; Wang Y; Anderson KC; Ritz J
    Blood; 1998 May; 91(10):3671-80. PubMed ID: 9573003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion.
    Orsini E; Alyea EP; Schlossman R; Canning C; Soiffer RJ; Chillemi A; Neuberg D; Anderson KC; Ritz J
    Bone Marrow Transplant; 2000 Mar; 25(6):623-32. PubMed ID: 10734296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
    Jones SC; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in the T-cell receptor V beta gene repertoire after allogeneic hematopoietic stem cell transplantation.
    Liu QF; Li YQ; Yang D; Zhang Y; Yang LJ; Chen SH; Sun J; Liu XL; Zhou SY
    Chin Med J (Engl); 2004 Mar; 117(3):413-8. PubMed ID: 15043783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?
    Radujkovic A; Guglielmi C; Bergantini S; Iacobelli S; van Biezen A; Milojkovic D; Gratwohl A; Schattenberg AV; Verdonck LF; Niederwieser DW; de Witte T; Kröger N; Olavarria E;
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1230-6. PubMed ID: 25797175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Donor regulatory T cells identified by FoxP3 expression but also by the membranous CD4+CD127low/neg phenotype influence graft-versus-tumor effect after donor lymphocyte infusion.
    Hicheri Y; Bouchekioua A; Hamel Y; Henry A; Rouard H; Pautas C; Beaumont JL; Kuentz M; Cordonnier C; Cohen JL; Maury S
    J Immunother; 2008; 31(9):806-11. PubMed ID: 18833007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modified donor lymphocyte infusion-associated acute graft-versus-host disease after haploidentical T-cell-replete hematopoietic stem cell transplantation: incidence and risk factors.
    Yan CH; Liu DH; Xu LP; Liu KY; Zhao T; Wang Y; Chen H; Chen YH; Han W; Huang XJ
    Clin Transplant; 2012; 26(6):868-76. PubMed ID: 22432715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion.
    Claret EJ; Alyea EP; Orsini E; Pickett CC; Collins H; Wang Y; Neuberg D; Soiffer RJ; Ritz J
    J Clin Invest; 1997 Aug; 100(4):855-66. PubMed ID: 9259585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tracking ex vivo-expanded CD4+CD25+ and CD8+CD25+ regulatory T cells after infusion to prevent donor lymphocyte infusion-induced lethal acute graft-versus-host disease.
    Xia G; Kovochich M; Truitt RL; Johnson BD
    Biol Blood Marrow Transplant; 2004 Nov; 10(11):748-60. PubMed ID: 15505606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation.
    Nikiforow S; Kim HT; Daley H; Reynolds C; Jones KT; Armand P; Ho VT; Alyea EP; Cutler CS; Ritz J; Antin JH; Soiffer RJ; Koreth J
    Haematologica; 2016 Oct; 101(10):1251-1259. PubMed ID: 27354021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of donor CD4+CD25+ regulatory T cells on hematopoietic and immune reconstitution, GVHD and disease-free survival after allogeneic hematopoietic stem cell transplantation].
    Yang K; Fan ZP; Liu QF; Zhang Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Apr; 28(4):537-41. PubMed ID: 18495584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
    Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
    Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CTLA-4 blockade following relapse of malignancy after allogeneic stem cell transplantation is associated with T cell activation but not with increased levels of T regulatory cells.
    Zhou J; Bashey A; Zhong R; Corringham S; Messer K; Pu M; Ma W; Chut T; Soiffer R; Mitrovich RC; Lowy I; Ball ED
    Biol Blood Marrow Transplant; 2011 May; 17(5):682-92. PubMed ID: 20713164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clonal expansion of CD8+ T cells reflects graft-versus-leukemia activity and precedes durable remission following DLI.
    Schultze-Florey CR; Kuhlmann L; Raha S; Barros-Martins J; Odak I; Tan L; Xiao Y; Ravens S; Hambach L; Venturini L; Stadler M; Eder M; Thol F; Heuser M; Förster R; Ganser A; Prinz I; Koenecke C
    Blood Adv; 2021 Nov; 5(21):4485-4499. PubMed ID: 34535011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T cell receptor repertoires after adoptive transfer of expanded allogeneic regulatory T cells.
    Theil A; Wilhelm C; Kuhn M; Petzold A; Tuve S; Oelschlägel U; Dahl A; Bornhäuser M; Bonifacio E; Eugster A
    Clin Exp Immunol; 2017 Feb; 187(2):316-324. PubMed ID: 27774628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.
    Giver CR; Montes RO; Mittelstaedt S; Li JM; Jaye DL; Lonial S; Boyer MW; Waller EK
    Biol Blood Marrow Transplant; 2003 Oct; 9(10):616-32. PubMed ID: 14569558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.